Ion

The Growing Prevalence Of Respiratory Allergies Will Propel The Car Air Purifier Market To More Than $2 Billion By 2026 - By The Business Research Company

Retrieved on: 
Thursday, November 24, 2022
Aerosol, Throat irritation, Filter (signal processing), Ion, EPA, Allergy, Headache, Nose, Volatile organic compound, Liver, Animal, Kidney, Xylene, Cancer, Human, Pollen, European Academy of Allergy and Clinical Immunology, Ozone, Atmosphere, Nausea, Eye, Organic compound, Growth, Central nervous system, Union, Dust, Incidence, Environmental remediation

Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.

Key Points: 
  • Car air purifiers will be needed to protect people from contaminated outdoor air when traveling in cars.
  • Thus, the increase in the incidence of respiratory allergies will bolster the demand for car air purifier market.
  • As per the car air purifier market analysis , the introduction of antimicrobial filters is gaining popularity in the car air purifier market.
  • Safety concerns with car air purifiers are expected to be a limiting factor for the growth of the car air purifier market during the forecast period, according to our car air purifier outlook.

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 15, 2022
Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, B7-H3, Biology, Environment, Mining, Monoclonal antibody, ASH, Janssen, Growth, Antibody, Royal commission, New Drug Application, CD3, Algorithm, National Medical Products Administration, Conference, AstraZeneca, Regulation of tobacco by the U.S. Food and Drug Administration, Form 10-Q, Sale, European Commission, Failure, Animal, Therapy, B-cell maturation antigen, Investigational New Drug, Chronic inflammatory demyelinating polyneuropathy, Union, Exposition, CD38, Food, Ion, Society, Research, Heart, Patient, Pharmaceutical industry, Vaccine

OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates.
  • OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) until its spin-off as an independent publicly traded company as of November 1, 2022.
  • As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here .
  • Net loss for the third quarter of 2022 was $12.6 million, compared with a net loss of $7.9 million for the same period in 2021.

Mass Spectrometry Market Report 2022: Massive Implications for Clinical Medicine Driving Adoption

Retrieved on: 
Tuesday, November 15, 2022
LC/MS, Atomic mass, CRO, Technology, Biology, Biotechnology, Medicine, Mass spectrometry, GC/MS, Physics, Research, Adoption, FTMS, CMO, Chemistry, Protein, Ion, Mass, Retail, Uranium

The mass spectrometer market is broadly segmented on the basis of mass spectrometry platforms such as hybrid mass spectrometry and single mass spectrometry.

Key Points: 
  • The mass spectrometer market is broadly segmented on the basis of mass spectrometry platforms such as hybrid mass spectrometry and single mass spectrometry.
  • While single mass spectrometry is further sub-segmented into Time-of-Flight (TOF) MS, Orbitrap MS and Quadrupole The hybrid mass spectrometry segment held the largest share in the global mass spectrometry market by platform.
  • The growing array of applications of mass spectrometry is driving the global mass spectrometry market.
  • As of the current market scenario, North America is the largest regional market for mass spectrometry with U.S. dominating the North America mass spectrometry market.

Cosmo Prof Launches New Platform Enabling Stylists to Build More Profitable Businesses

Retrieved on: 
Thursday, November 10, 2022
Sally Beauty Holdings, CosmoProf, Marketing, NYSE, OPI, Partnership, Skin care, Education, Technology, Multimedia, Ion, Cosmo, Nail, Consultant, Face, API, View, Clairol, Human, Conair, Zone, Program, Nikon, Entrepreneurship, Armstrong, Goldwell, L'Oréal, SBH, Industry, Matrix, Wella, Online shopping

After looking into consumer insights and the industry overall, Cosmo Prof recognized a gap in meeting stylists' business and entrepreneurial needs.

Key Points: 
  • After looking into consumer insights and the industry overall, Cosmo Prof recognized a gap in meeting stylists' business and entrepreneurial needs.
  • With a free and customizable digital platform backed by Cosmo Prof's expansive assortment and fulfillment capabilities, stylists can easily sell products directly to their clients 24/7 while earning commission."
  • Cosmo Prof knows stylists are the ultimate influencers for their clients, with the ability to directly impact purchasing decisions based on their trusted relationships.
  • Stylists don't have to worry about shipment, fulfillment, or inventory management Cosmo Prof handles all orders through SalonHQ's innovative e-commerce technology.

Mass Spectrometry Market Report 2022: Expanding Applications in Life Sciences and Pharmaceutical Industries Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Research, Science, FTMS, Physics, Adoption, Mass spectrometry, Chemistry, Biotechnology, LC/MS, GC/MS, CMO, Ion, Medicine, Mass, Protein, Biology, Research, Atomic mass, CRO, Technology, Retail, Uranium

The mass spectrometer market is broadly segmented on the basis of mass spectrometry platforms such as hybrid mass spectrometry and single mass spectrometry.

Key Points: 
  • The mass spectrometer market is broadly segmented on the basis of mass spectrometry platforms such as hybrid mass spectrometry and single mass spectrometry.
  • While single mass spectrometry is further sub-segmented into Time-of-Flight (TOF) MS, Orbitrap MS and Quadrupole The hybrid mass spectrometry segment held the largest share in the global mass spectrometry market by platform.
  • The growing array of applications of mass spectrometry is driving the global mass spectrometry market.
  • As of the current market scenario, North America is the largest regional market for mass spectrometry with U.S. dominating the North America mass spectrometry market.

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer

Retrieved on: 
Wednesday, November 9, 2022
Christer, Environment, CPO, Antibody, Proteomics, Patient, MD, Ion, IRM, Board, Biotechnology, Orion Corporation, Cancer, CDO, CBO, Medicinal chemistry, CFO, Proteome, Pain, CSO, Eli Lilly, Doctor of Philosophy, Roche, Leadership, Protein, Teva Pharmaceuticals, Senior management, The Advisory Board Company, Epitope, AstraZeneca, Psychiatry, Neurodegeneration, Biochemistry, Therapy, Technology, CEO, Pharmaceutical industry, Fine chemical, Pharmacology, Oblique

During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.

Key Points: 
  • During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.
  • Christer's latest position was interim Chief Executive Officer (CEO) for Vivesto, a pharmaceutical manufacturing company, Uppsala, Sweden.
  • This has resulted in the selection of an external candidate, Christer Nordstedt, with a detailed understanding of the biotechnology market and Oblique Therapeutics AB's strategic issues.
  • The whole Oblique Therapeutics team wishes Dr. Christer Nordstedt a warm welcome and the best of luck and success in his professional endeavor.

Oblique Therapeutics is delighted to announce the appointment of Christer Nordstedt M.D. PhD. as Chief Executive Officer

Retrieved on: 
Wednesday, November 9, 2022
Christer, Environment, CPO, Antibody, Proteomics, Patient, MD, Ion, IRM, Board, Biotechnology, Orion Corporation, Cancer, CDO, CBO, Medicinal chemistry, CFO, Proteome, Pain, CSO, Eli Lilly, Doctor of Philosophy, Roche, Leadership, Protein, Teva Pharmaceuticals, Senior management, The Advisory Board Company, Epitope, AstraZeneca, Psychiatry, Neurodegeneration, Biochemistry, Therapy, Technology, CEO, Pharmaceutical industry, Fine chemical, Pharmacology, Oblique

During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.

Key Points: 
  • During his career, Christer has been responsible for large global research projects and leadership in both management, executive, and board roles.
  • Christer's latest position was interim Chief Executive Officer (CEO) for Vivesto, a pharmaceutical manufacturing company, Uppsala, Sweden.
  • This has resulted in the selection of an external candidate, Christer Nordstedt, with a detailed understanding of the biotechnology market and Oblique Therapeutics AB's strategic issues.
  • The whole Oblique Therapeutics team wishes Dr. Christer Nordstedt a warm welcome and the best of luck and success in his professional endeavor.

Salipro Biotech enters into collaboration and license agreement with Sanofi to advance discovery programs

Retrieved on: 
Tuesday, November 8, 2022
Drug discovery, G protein-coupled receptor, Membrane protein, Technology, CEO, IP, Research, Therapy, Antigen, Ion, Fine chemical, Sanofi

STOCKHOLM, Nov. 8, 2022 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.

Key Points: 
  • STOCKHOLM, Nov. 8, 2022 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.
  • "We are excited to work closely with the innovative team at Sanofi to accelerate their drug discovery efforts against a selected membrane protein drug target" said Jens Frauenfeld, CEO of Salipro Biotech.
  • Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics.
  • Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs.

Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease

Retrieved on: 
Friday, November 4, 2022
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Apolipoprotein L1, Research, Kidney disease, Kidney, Society, Bridge, Human, Chronic kidney disease, APOL1, Population, Vanderbilt University, Therapy, Albuminuria, Urine, HIV disease progression rates, Compass, CKD, Genetics, Data science, ASN, Risk, Ion, Drug development, Disease, Technology, Toxicity, Gene, Patient, Caregiver, Pharmaceutical industry, Maze

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its APOL1 inhibitor program as a treatment for chronic kidney disease (CKD) and describing the role of APOL1 variants in causing and protecting from kidney disease.

Key Points: 
  • Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its APOL1 inhibitor program as a treatment for chronic kidney disease (CKD) and describing the role of APOL1 variants in causing and protecting from kidney disease.
  • While there are no targeted therapies to address the underlying cause of disease available today, recent human genetic findings suggest that pharmacologic inhibition of APOL1 pore function may treat APOL1-mediated kidney disease.
  • Maze is advancing an APOL1 small molecule inhibitor program, with preclinical data demonstrating dose dependent responses to treatment and supporting its potential as a treatment for certain APOL1-mediated kidney diseases.
  • In experiments conducted by Maze Therapeutics, the p.N264K variant reduces conductance of ions through the APOL1 pore and thereby suppresses the toxicity of APOL1 to kidney cells.

OmniAb to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Thursday, November 3, 2022
Science, Software, Research, Pharmaceutical, General Health, Health, Data Management, Technology, Animal, Therapy, Heart, Algorithm, Ion, Industry, Antibody, Investor, Conference, Biology, Monoclonal antibody, Credit Suisse, NASDAQ, Technology, Mining, Vaccine

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences.
  • Management will be participating in a fireside chat on Wednesday, November 9th at 11:35 a.m. Pacific time and will be hosting one-on-one meetings with investors.
  • The fireside chat will be webcast live and available for replay in the Investors section of OmniAbs website by clicking here .
  • OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.